Hyperion Therapeutics, which is focused on the treatment of orphan diseases of the liver relating to the urea cycle, raised $50 million by offering 5 million shares at $10.00, below the range of $11.00 to $13.00. Because Hyperion had planned to offer only 4.2...read more
Hyperion Therapeutics, a biotech focused on the treatment of urea cycle disorders and hepatic encephalopathy, announced terms for its IPO on Friday. The South San Francisco, CA-based company plans to raise $50 million by offering 4.2 million shares at a price...read more
Hyperion Therapeutics, a biotech focused on the treatment of urea cycle disorders and hepatic encephalopathy, filed on Friday with the SEC to raise up to $58 million in an initial public offering. The company's lead candidate, Ravicti, is under FDA review and is...read more
Hyperion Therapeutics prices IPO at $10.00, below the range
Hyperion Therapeutics, which is focused on the treatment of orphan diseases of the liver relating to the urea cycle, raised $50 million by offering 5 million shares at $10.00, below the range of $11.00 to $13.00. Because Hyperion had planned to offer only 4.2...read more
8 US IPOs planned for the week of Jul 23
The following IPOs are expected to price this week:
AmREIT (AMRE), a full service REIT that owns and operates neighborhood and community shopping centers, plans to...read more
Biotech Hyperion Therapeutics sets terms for $50 million US IPO
Hyperion Therapeutics, a biotech focused on the treatment of urea cycle disorders and hepatic encephalopathy, announced terms for its IPO on Friday. The South San Francisco, CA-based company plans to raise $50 million by offering 4.2 million shares at a price...read more
Biotech Hyperion Therapeutics files for $58 million US IPO
Hyperion Therapeutics, a biotech focused on the treatment of urea cycle disorders and hepatic encephalopathy, filed on Friday with the SEC to raise up to $58 million in an initial public offering. The company's lead candidate, Ravicti, is under FDA review and is...read more